Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Type I IFN family members: Similarity, differences and interaction

Maria Rosaria Capobianchi a, Elena Uleri b, Claudia Caglioti a, Antonina Dolei b,*

a Laboratory of Virology, National Institute for Infectious Diseases “L. Spallanzani”, Via Portuense 292, Rome, Italy
b Department of Biomedical Sciences, University of Sassari, Sassari, Italy

ABSTRACT

Interferons (IFN) are key cytokines with multifaceted antiviral and cell-modulatory properties. Three distinct types of IFN are recognized (I–III) based on structural features, receptor usage, cellular source and biological activities. The action of IFNs is mediated by a complex, partially overlapping, transcriptional program initiated by the interaction with specific receptors. Genetic diversity, with polymorphisms and mutations, can modulate the extent of IFN responses and the susceptibility to infections. Almost all viruses developed mechanisms to subvert the IFN response, involving both IFN induction and effector mechanisms. Interactions between IFN types may occur, for both antiviral and cell-modulatory effects, in a complex interplay, involving both synergistic and antagonistic effects. Interferon-associated diseases, not related to virus infections may occur, some of them frequently observed in IFN-treated patients. On the whole, IFNs are pleiotropic biologic response modifiers, that, upon activation of thousands genes, induce a broad spectrum of activities, regulating cell cycle, differentiation, plasma membrane molecules, release of mediators, etc., that can be relevant for cell proliferation, innate and adaptive immunity, hematopoiesis, angiogenesis and other body functions.

1. Introduction

Interferon (IFN) was first discovered as an antiviral agent during studies on virus interference [1,2]. Isaacs and Lindenmann reported in 1957 that influenza virus-infected chick cells produced a secreted factor that mediated the transfer of a virus-resistant state active between both homologous and heterologous viruses [1]. This seminal observation, along with similar findings described by Nagano and Kojima in 1958 [2], set the stage for subsequent studies that led to the elucidation of the IFN system in exquisite detail [3].

Almost 60 years after the discovery of Isaacs and Lindenmann, considerable progress has been made toward answering multiple questions about IFN family members and their effects on the virus-host interaction. Advances made while elucidating the IFN system contributed significantly to our understanding in multiple areas of mammalian cell biology and biochemistry, ranging from the pathways of signal transduction to the biochemical mechanisms of transcriptional and translational control to the molecular basis of viral pathogenesis [3], and led to the development of the first “cytokine-based” therapy in the 70s, now licensed worldwide for viral disease, malignant and even immune disorders [4].

Abbreviations: ADAR1, adenosine deaminase acting on RNA 1; AP-1, activator protein 1; APCs, antigen presenting cells; ATFS, activating transcription factor 6; BCG, bacille Calmette–Gueuin; cGAS, cyclic GMP-AMP synthase; CHIKV, Chickungunya virus; CRF2, class II cytokine receptor family; ds, double strand; EAE, experimental allergic encephalomyelitis; EM, environmental mycobacteria; EMVC, encephalomyocarditis virus; GA, gamma interferon activation site; hCMV, human Cytomegalovirus; HCV, hepatitis C virus; HSE, herpes simplex encephalitis; HSV-1, herpes simplex virus-1; IFN16, gamma-interferon-inducible protein 16; IFN, interferon; IFNAR, interferon alpha receptor; IFNGR, interferon gamma receptor; IL, interleukin; IPS-1, interferon promoter-stimulating factor 1; IRAK-4, interleukin-1 receptor-associated kinase 4; IRF, interferon regulatory factor; ISGF3, interferon-stimulated gene factor 3; ISRE, interferon stimulated response element; JAK, Janus kinase; LASV, Lassa virus; MAPK, mitogen-activated protein kinases; MDAS, melanoma differentiation-associated protein 5; MHC, major histocompatibility complex; MS, multiple sclerosis; MSMD, Mendelian susceptibility to mycobacterial disease; MxA, Myxovirus Resistance Gene A; NEMO, nuclear factor (NF)-κB essential modulator; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NK, natural killer cells; OAS, 2′,5′-oligo adenylate synthetase A; p300/CREB-binding protein; PD-1, programmed death ligand 1; PKR, dsRNA-dependent protein kinase; PRRs, pattern-recognition receptors; RIG-1, retinoic-acid-inducible gene 1; SAMHD1, SAM domain and HD domain-containing protein 1; SARS, severe acute respiratory syndrome; SARS-CoV, severe acute respiratory syndrome-associated coronavirus; SNPs, single nucleotide polymorphisms; SOCS, suppressor of cytokine signaling; ss, single strand; STAT, Signal Transducer and Activator of Transcription; Th, lymphocytes T helper; TLR, Toll-like receptor; TREX1, three prime repair exonuclease 1; TYK2, tyrosine kinase 2; VSV, vesicular stomatitis virus; VZV, Varicella-Zoster virus; WNV, West Nile virus.

* Corresponding author at: Department of Biomedical Sciences, University of Sassari, viale San Pietro 42B, 07100 Sassari, Italy. Tel.: +39 3204299685; fax: +39 079212345.

E-mail address: dolevi@uniss.it (A. Dolei).
2. Unraveling the complexity of the interferon system

After the first discovery of Type I IFN during 1950s [1] and Type II IFN in 1965 [5], in 2003 two groups independently reported the discovery of a trio of novel interferon-like cytokines that are referred to as either IFNλ1, λ2, and λ3 or interleukin-29 (IL-29), IL-28A, and IL-28B, respectively [6,7], and constitute type III IFN. Both groups also identified and characterized the novel receptor, IFNλR1 (also known as IL-28RA), through which these cytokines mediate their biological activities [8].

2.1. Interferon genes and proteins

IFNs are key cytokines in the establishment of a multifaceted antiviral response. Three distinct types of IFNs are now recognized (types I, II, and III) based on their structural features, receptor usage and biological activities [8]. A synopsis of the major features of IFN family member components is reported in Table 1. Type I IFN family in humans consists of 14 IFNα species [9] and a single species of IFNβ, IFNγ, IFNω, and IFNε; whereas there is only one type II IFN known as IFNγ. All the type I IFN components lack introns and are clustered on the short arm of chromosome 9 in human and chromosome 4 in mouse genome. The single IFNγ gene possesses three introns and maps to the long arm of chromosome 12 in human, and chromosome 10 in mouse genome. Although some IFNs are modified post-translationally by N- and O-glycosylation, the major human IFNs subspecies are not glycosylated [3]. IFNα and IFNβ gene products appear to function as monomers, whereas IFNγ appear to function as homodimers [10]. On the other hand, IFNλ genes are clustered together on human 19 or murine 7 chromosome. The IFNλ3 gene (IL28B) is transcribed in the opposite direction of the IFN-α1 (IL29) and IFNα2 (IL28A) genes [8].

Although all IFNs are important mediators of antiviral protection, their roles in antiviral defense vary. Type I IFNs have four major functions. First, they induce cell-intrinsic antimicrobial states in infected and neighboring cells that limit the spread of infectious agents, particularly viral pathogens. Second, they modulate innate immune responses in a balanced manner that promotes antigen presentation and natural killer cell functions while restraining pro-inflammatory pathways and cytokine production. Third, they activate the adaptive immune system, thus promoting the development of high-affinity antigen-specific T and B cell responses and immunological memory [9]. Fourth, they present an antiproliferative activity: in fact, several recent studies showed type I IFN-induced autophagy in multiple cancer cell lines highlighting a new function of type I IFN as an inducer of autophagy. This new function of type I IFN may play an important role in viral clearance, antigen presentation, inhibition of proliferation, as well as a positive feedback loop for the production of type I IFN [11]. Type I IFNs are protective in acute viral infections but can have either protective or deleterious roles in bacterial infections and autoimmune diseases. Most cell types produce IFNβ, whereas haematopoietic cells, particularly plasmacytoid dendritic cells, are the predominant producers of IFNα. Type I IFN production is induced after the sensing of microbial products by pattern-recognition receptors (PRRs) [4–6] and by cytokines [9]. IFNγ is mainly secreted by T lymphocytes, natural killer cells and antigen presenting cells (APCs) such as monocytes, macrophages and dendritic cells. IFNγ secretion by natural killer (NK) cells and professional antigen presenting cells is likely to be important in early host defense against infection, whereas T lymphocytes become the major source of IFNγ in the adaptive immune response. IFNγ production is controlled by cytokines secreted by antigen presenting cells, most notably IL12 and IL18. Macrophage recognition of many pathogens induces the secretion of IL-12 and several chemokines. These chemokines attract natural killer cells to the site of inflammation, and IL-12 promotes IFNγ synthesis in these cells [12]. IFNγ also plays a central role in the development of antitumor immune responses, and it can amplify the induction of antiviral activity by IFNα or IFNβ. Therefore, type I and type II IFN often work together to activate a variety of innate and adaptive immune responses that result in the induction of effective antitumor immunity and the elimination of viral infections [10,13]. On the other hand, the IFNα signal transduction cascade is very similar to that induced by type I IFNs (IFNα or IFNβ). Therefore, it is not surprising that type I and type III IFNs exert similar biological activities. Both types of IFN possess the intrinsic ability to induce antiviral activity in cells [8]. In fact, the IFNλs are usually coexpressed together with type I IFNs by virus infected cells [6,7].

2.2. IFN receptors

IFNs are part of the larger family of class II cytokines that also includes 6 IL-10-related cytokines: IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26 [14–16] as well as several viral IL-10-related cytokines [17]. Class II cytokines all signal via receptors that share common motifs in their extracellular domains, and are indicated as class II cytokine receptor family (CRF2). Consequently, IFNs and the IL-10-related cytokines are sometimes referred to as “CRF2 cytokines” [8]. However, although the tertiary structure of IFNγ resembles that of IL-10, its primary structure significantly diverges from all of the CRF2 ligands. The most recent addition to the CRF2 family members, type III IFN or IFNλ, demonstrates structural features of the IL-10-related cytokines but also induces antiviral activity in a variety of target cells, which supports their functional classification as a new IFN type [6,7]. Phylogenetically, the IFNα genes reside somewhere between the type I IFN and IL-10 gene families. Amino acid sequence comparison shows that the type III IFN members exhibit about 5–18% identity with either type I IFN members or the IL-10-related cytokines. The IFNα proteins bind and signal through a receptor complex composed of the unique IFNαR1 chain (also known as IL-28RA) and the shared IL-10R2 chain which is also a part of the receptor complexes for IL-10, IL-22, and IL-26. In contrast, all type I IFN members exert their biological activities

| IFN type | Name (no. of genes) | Location in human chromosomes | Receptors |
|----------|----------------------|-------------------------------|-----------|
| Type I   | IFNα (14), IFNβ (1), IFNω (1) | Chromosome 9 | IFNαR1 and IFNαR2 (also known as IFNAR1 and IFNAR2) |
|          | IFNγ (1), IFNε (1)       |                  |           |
| Type II  | IFNγ (1)               | Chromosome 12             | IFNγR1 and IFNγR2 (also known as IFNGR1 and IFNGR2) |
| Type III | IFNλ (3)               | Chromosome 19             | IFNAR1 (also known as IL-28RA) and IL-10R2 |
through a heterodimeric receptor complex composed of the IFNαR1 (IFNAR1) and IFNαR2 (IFNAR2) chains, and type II IFN (IFNγ) engages the IFNγR1 (IFNGR1) and IFNγR2 (IFNGR2) chains to assemble its functional receptor complex [8].

In the canonical type 1 IFN-induced signaling pathway described over 25 years ago, IFNAR engagement was shown to activate the receptor-associated protein tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which phosphorylate the latent cytoplasmic transcription factors Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2. Tyrosine-phosphorylated STAT1 and STAT2 dimerize and translocate to the nucleus, where they assemble with IFN-regulatory factor 9 (IRF9) to form a trimolecular complex called IFN-stimulated gene factor 3 (ISGF3). ISGF3 binds to its cognate DNA sequences, which are known as IFN-stimulated response elements (ISREs), thereby directly activating the transcription of ISGs, many of which establish a cellular antiviral state. ISG-encoded proteins restrain pathogens by several mechanisms, including the inhibition of viral transcription, translation and replication, the degradation of viral nucleic acids and the alteration of cellular lipid metabolism. Cellular responses to IFNAR ligation are cell type- and context-dependent and vary during the course of an immune response [9]. Therefore, as said above, although the IFNα members do not use the IFNα receptor complex for signaling, signaling through either IFNα or IFNα receptor complexes results in the activation of the same Jak-STAT signal transduction cascade [8].

2.3. Genetic variations affecting IFN response

The relevance of genetic and epigenetic variations in determining the range of susceptibility and of clinical severity of several diseases, including those caused by infectious agents, in the human population is well known. Therefore, considering the importance of IFN system in antiviral defense mechanisms and, more broadly, in immune response, it is not surprising that genetic and epigenetic variations within the IFN genes and in those associated with sensing/signaling/response are associated with a range of diseases. In recent years, inborn errors affecting the production of IFN family members have been reported in human patients. Insights into the specific role of human IFNα/β and IFN-α–induction pathways in anti-viral immunity have been provided by the study of herpes simplex encephalitis (HSE), the most common sporadic viral encephalitis in Western countries caused by the almost ubiquitous and almost innocuous herpes simplex virus-1 (HSV-1). HSE has been shown to result from a new group of primary immunodeficiencies; the first two genetic etiologies of this disease have been identified as UNC-93B and Toll-like receptor 3 (TLR3) deficiencies. These discoveries demonstrated the critical role of the UNC-93B-dependent, TLR3-IFNα, IFNβ, and IFNλ pathway in immunity to HSV-1 in children. The wide redundancy of other TLR-mediated IFN induction pathways is probably responsible for the lack of increased susceptibility to common viral infection and HSE that is reported for IL-1 receptor-associated kinase 4 (IRAK-4)-deficient patients, who display impaired production of IFNα, IFNβ, and IFNλ following the activation of TLR7, TLR8, and TLR9 [18]. Increased susceptibility to multiple viruses, including HSV-1, has been reported also for inborn errors affecting the response to IFN family members, such as STAT1 or TYK2 deficiency [19]. In addition, IFNγ deficiencies confer Mendelian susceptibility to mycobacterial disease (MSMD) that is a rare congenital syndrome characterized by the occurrence of severe, often disseminated, clinical disease, caused by weakly virulent mycobacterial species, such as bacille Calmette-Guérin (BCG) vaccines and non-tuberculous environmental mycobacteria (EM), in otherwise healthy individuals [18]. IFNγ production is controlled by cytokines secreted by myeloid cells, including IL-12 and IL23. Disorders of six genes of the IL-12/23–IFNγ circuit were discovered since 1996, demonstrating the critical role of this circuit in protective immunity to mycobacteria [20,21]. The role of IL-12–dependent IFNγ production has been confirmed by recent studies, showing that defects in IL-12p40 or IL-12Rβ1 and specific mutations in NEMO [nuclear factor (NF)-κB essential modulator] are specifically associated with impaired IFNγ-mediated immunity and clinical MSMD [18]. Furthermore, over 347 IFNγ gene variants and several single nucleotide polymorphisms (SNPs) in either IFNγ promoter region or in NFκB binding regions, have been described in multiple ethnic populations, often affecting IFNγ gene expression. Many of these variants appear to modulate susceptibility not only to infectious diseases, especially tuberculosis and viral hepatitis, but also to some non-infectious conditions such as aplastic anemia and psoriasis; susceptibility to cervical cancer, that is in a position to bridge viral and non viral mechanisms, is also influenced by host genetic factors targeting IFNγ reviewed in [22]. Besides genetic variants, several epigenetic modifications are also described, increasing IFNγ expression in Th1 lymphocytes and reducing IFNγ expression in Th2 lymphocytes. Increased methylation of IFNγ promoter and consequent decreased expression of this gene is associated with asthma; on the contrary, decreased methylation is associated with increased diastolic blood pressure, biliary atresia, dental pulp inflammation, and chronic periodontitis [22]. Overall, human inborn errors affecting IFN system have provided conclusive evidence that the members of IFN family are crucial for protective immunity and innate defense against viral, bacterial and non-infectious diseases. However non-redundant role of these members seems to arise, with a certain polarization of protection, as IFNγ seems to be essential for anti-mycobacterial immunity, whereas IFNα/β and IFNλ are essential for anti-viral immunity [18].

3. Viral strategies to counteract the IFN system

Virus survival and spread into the host depend on the ability to avoid recognition and control by the host defense. Therefore viruses use immunoevasion strategies to counteract the host defenses, particularly against effectors of the innate immunity, as the interferon system and the interferon-induced molecules (Fig. 1). Virtually all viruses of mammals have developed multiple mechanisms of immune evasion. Viruses with wide genomes and well adapted to the host (Poxviruses, Herpesviruses) have multiple tools to interfere with the IFN system. In general, differences in the strategies lie on the host cell machinery, rather than on the IFN type. Viruses can evade host defenses through inhibition of IFN induction and/or by inhibition of their signaling pathways, through activation of the IFN regulatory factors (IRFs), the Signal Transducer and Activator of Transcription (STAT) factors, or the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [23–25]. Viruses developed multiple escape strategies. The IFN-induced Mx pathway is active against a wide range of viruses by blocking primary transcription of the incoming viral genome, by its virionic polymerase, but so far there is no evidence for a virus-coded inhibitor of Mx. Since in the presence of Mx, the virus cannot replicate, the generation of Mx escape mutants/strategies is virtually impossible. Nevertheless, viruses subvert the Mx system, simply by suppressing IFN production in the host (see below), thereby avoiding Mx expression in potential target cells [26].

3.1. Virus inhibition of upstream mediators of IFN production

The cell can detect an ongoing viral invasion, through sensors located in the cytoplasm or on the membrane of endosomes. These molecules include the cytosolic retinoic-acid-inducible gene 1
dsRNA produced and negative-sense dsRNA activate syncytial (picornaviruses two viruses vast are filoviruses rhabdoviruses)

TLR3 dependent

AP-1, respiratory (RIG-1)

106

transducers

degradation (Influenza 1.

A

simplified genome (such helicases, types C)

AP-1

activators

1;

IFN-inducible

1;

viral signaling pathways.

after the viral entry and uncoating, the detection of viral genome by cytoplasmic or endosomal sensors is prevented by many viral strategies which, on the whole, target the nuclear translocation of translation factors (NF-κB, IRF-3, AP-1); other strategies include the block of upstream mediators such as MDA-5 or TLRs.

(TLR), as TLR3, 7, 8, and 9 [23,24,27]. The vast majority of human infections is due to RNA viruses; those with a dsRNA genome (as rotaviruses and other reoviruses) are detected by TLR3 or by MDA5. During replication of positive-sense ssRNA viruses (picornaviruses like hepatitis A virus and poliovirus, flaviviruses like hepatitis C virus and West Nile virus, coronaviruses like severe acute respiratory syndrome (SARS) virus), a dsRNA intermediate form is produced in the cytoplasm, which is recognized by MDA5. The latter two families may also be sensed by RIG-I. The viruses with a negative-sense ssRNA genome (orthomyxoviruses as influenza A virus, paramyxoviruses like measles virus, mumps virus, respiratory syncytial virus, parainfluenza virus, and Newcastle disease virus, rhabdoviruses like rabies virus and vesicular stomatitis virus, filoviruses like Ebola virus, hantaviruses, Borna disease virus, etc.) activate RIG-I with their ssRNA genome. Double-stranded DNA viruses (such as α, β and γ herpesviruses, adenoviruses, poxviruses) are sensed by TLR9; by convergent they can also produce dsRNA and thus activate TLR3, IFN-inducible dsRNA-dependent protein kinase (PKR), and also MDA5 and/or RIG-I.

Retroviruses (such as HIV-1 and human T-lymphotropic virus I and II) have a diploid positive-sense ssRNA genome in the virion, that is reverse transcribed into dsDNA provirus, which is then integrated into the host genome. Retroviral ssRNA is sensed by TLR7 and TLR8. The reverse transcription intermediates are recognized by the cytosolic IFI16 and cGAS DNA sensors, and this leads to the initiation of the type I IFN antiviral response, pyroptosis and apoptosis, under the regulation by host restriction factors such as SAMHD1 and TREX1.

3.2. Viral escape of signaling leading to IFN production

After virus sensing, a series of transcription factors are activated within the cell, leading to IFN production, i.e. IRF-3, NF-κB, the activator protein 1 (AP-1), and the chromatin remodeling associated p300/CREB-binding protein (p300/CBP). These activated molecules translocate to the nucleus and interact with the IFN promoter sequences, to upregulate the expression of interferon genes. IRF-3 activity is hampered by human papillomavirus (HPV) through the E6 protein, by the Influenza A virus through the NS1 protein, that is thought to bind and sequester viral dsRNA, to protect it from cell intrinsic viral RNA
3.3. Viral inhibition of the JAK-STAT signaling pathway

This signaling pathway (that acts through the JAK and TYK2 kinases, IRF-9, and STAT proteins) varies with the IFN type, since the IFNα/β receptor on the plasma membrane activates the JAK1 and TYK2 molecules, while the IFNγ receptor activates JAK1 and JAK2; by protein phosphorylation the signal is transmitted to the nucleus [30,31]. Many viruses counteract the JAK-STAT pathway by their V and C proteins, as Paramyxoviruses, rubiviruses, etc., whose V and C proteins block the induction of IFNβ and can degrade the STAT proteins or prevent their phosphorylation or limit their nuclear translocation [23]. This can make the cells unresponsive to both type I and type II interferons, as for the Sendai virus, or the cells do not respond to IFNα but still remain responsive to IFNγ, as it occurs for measles virus [32]. The VP24 protein of the lethal Ebola virus binds the karyopherin alpha nuclear transporter, to inhibit STAT1 nuclear transport and render cells refractory to IFNs [33].

3.4. Inhibition of IFN-induced antiviral effectors

Viruses (influenza virus, HCV, herpes simplex virus) can also induce the suppressor of cytokine signaling (SOCS) proteins, negative regulators of the JAK-STAT signaling [23,34]. The already mentioned virus-coded C and V proteins can interfere with the IFN-induced PKR (protein kinase R) and ADAR1 (adenosine deaminase acting on RNA 1) enzymes, thus preventing the inhibition of translation and the induction of apoptosis, thus helping virus presence and replication within the cell [35,36]. Complex viruses have multiple mechanisms to interfere with the IFN system; the various poxviruses are active against type I and type III interferons through a secreted protein, antagonize NF-κB and have a specific interferon-gamma-binding protein that interfere with the binding to the cell receptor [37–40]. Almost every step of the IFN response can be interfered by the vaccinia poxvirus: induction of IFNs, activation of the NF-κB and IRF-3 and of the JAK-STAT pathways, as well as the activity of the effectors of the antiviral state, such as those involving PKR and the 2′-5′-Oligoadenylate synthetase [37,41]. Recent studies have shown that the Acanthamoeba polyphaga mimivirus (APMV) may be pathogen for humans, causing pneumonia. In human PBMCs APMV replicates, inducing type I IFNs, but inhibiting IFN stimulated genes (ISG) induction by vireceptor and STAT-1 and STAT-2 dephosphorylation independent mechanisms; it is resistant to IFNα2, but sensitive to IFNβ [42].

4. Synergistic and antagonistic interactions

The ability of IFN family members to protect against various viral infections descends from the complex transcriptional programs they initiate. Each type of IFN can induce the expression of hundreds of genes to mediate various biological responses. Although IFNs are effective inhibitors of viruses such as vesicular stomatitis virus (VSV) and encephalomyocarditis virus (EMCV), almost all RNA and DNA viruses have evolved mechanisms to subvert the host IFN response, and are able to resist, at least in part, to the IFN-mEDIATE inhibition. However, several studies have shown that viruses normally resistant to the effects of type I or type II IFN separately, are susceptible to IFNs when used in combination. The reciprocal potentiation of type I or type II IFN is a well known phenomenon described since 1979 [43], and has been observed for both antiviral and antitumor effects [44]. Synergistic antiviral activity resulting from the contemporary presence of both IFN types has also been described in HIV-infected patients and in some autoimmune diseases [45]. It has been demonstrated that IFNα/β and IFNγ synergistically inhibit the replication of HSV-1 both in vitro and in vivo [46,47]. In addition, several reports have indicated that IFN family members used in combination have a synergistic antiviral activity against other viruses, such as hepatitis C virus (HCV) [48], Lassa virus (LASV) [49], Varicella-Zoster virus (VZV) [50], human Cytomegalovirus (hCMV) [47] and severe acute respiratory syndrome-associated coronavirus (SARS-CoV) [51,52]. Peng and collaborators tried to better understand the mechanisms underlying the synergism between type I and type II IFN in the inhibition of HSV-1 replication. They showed that IFNβ1 and IFNγ interaction is exploited through either an independent, i.e. inducing distinct gene categories, or a cooperative mechanism, i.e. inducing a common subset of genes at a level that is much higher than with either IFN alone. The genes cooperatively induced by IFNβ1 and IFNγ included those involved in apoptosis, RNA degradation and inflammatory response. As result, the combination of IFNβ1 and IFNγ induced more apoptosis and inhibited HSV-1 gene expression and DNA replication significantly more than treatment with either IFN alone [53].

While synergism between type I and type II IFN is well established, little is known about the effect of type I and type III IFNs combination, as available studies report contrasting information, with synergism reported for some viruses (i.e. HCV) [54,55], but not for other viruses (i.e. EMCV and HSV-2) [56]. In addition, antagonism for the intracellular pathways involved in antiviral activity has been reported [57]. In a recent study [58] possible synergism/antagonism between IFNα and/or IFNλ in the inhibition of virus replication (EMCV, WNV lineage 1 and 2, CHIKV and HSV-1) has been investigated in different cell lines. The results showed that IFNλ is less effective than IFNα for both the inhibition of virus replication, and that IFNα antagonized the IFNα-driven inhibition of virus replication. The findings on antiviral activity are paralleled by analogous trends in the induction of the molecular mediators of antiviral activity (MxA and 2′-5′OAS). An overview of the interactions between IFN family members is reported in Table 2.

5. Activities not related to viruses

Studies of the late Sixties revealed that the antiviral agent IFN was able also to suppress the growth of tumors [59]. Since then, IFNs were shown to be pleiotropic biologic response modifiers, that, upon activation of thousands genes [60] induce a broad spectrum of activities, regulating cell cycle, differentiation, expression of pivotal molecules on the plasma membrane, release of mediators, etc., that can be relevant for cell proliferation, innate

| Table 2 | Overview of synergistic and antagonistic interactions among IFN family members. See text for details and references. |
|---------|---------------------------------------------------------------|
| IFNs combination | Type of interaction | Outcome |
| IFNα or IFNβ | Synergy | Inhibition of HSV-1 replication |
| IFNα or IFNγ | Synergy | Inhibition of HCV replication |
| IFNα + IFNγ | Synergy | Inhibition of LAV replication |
| IFNβ + IFNγ | Synergy | Inhibition of VZV replication |
| IFNβ + IFNγ | Synergy | Inhibition of ICN3a replication |
| IFNα + IFNγ | Synergy | Inhibition of SARS-CoV replication |
| IFNγ + IFNγ | Synergy | Inhibition of HSV-1 replication |
| IFNα + IFNγ | Synergy | Inhibition of HCV replication |
| IFNα or IFNλ | Antagonism | Inhibition of EMCV and HSV-2 replication |
| IFNα + IFNλ | Antagonism | Inhibition of EMCV, WNV, CHIKV and HSV-1 replication |
and adaptive immunity, hematopoiesis, angiogenesis, and with important outcomes also for cancer, autoimmunity, and therapy [61,62]. A survey of the spectrum of biological activities of the interferons is reported in Table 3. Importantly, because of the multitude of IFN-induced genes, opposite effects can be determined by the same IFN, depending on timing and dosages, both in vitro and in vivo, as shown since the Seventies in the mouse Friend erythroleukemia cells [63,64]; IFN effects on patients were defined “Janus-like”, as IFNs may have both beneficial and detrimental effects, depending on the disease context [65].

### 5.1. Anti-proliferative activity

This property of all IFNs can help the host by depletion of infected cells, restrain excess cell-mediated immunity and inhibit angiogenesis, with consequent reduction of tumor growth; it may occur both in cancer and normal cells, in vitro and in vivo. Type II IFN is more effective than type I IFN (being IFNβ more potent than IFNα), while type III IFN is restrained by the low or limited presence of the specific receptor on the membrane of the target cells [66–68]. IFNβ has a greater receptor-binding affinity than IFNα, and this finding may account for the more potent and different antiproliferative and perhaps immunoregulatory actions of IFNβ [69]. The anti-growth activity of IFNs is mediated by arrest of the cell cycle and induction of caspases and apoptosis; it occurs in all the somatic cells tested, with differences depending on the IFN type and dosage [66,70]. The anti-proliferative activity of type III IFNs does not occur in all the receptor-positive cells but depends on the cell type, at variance with the antiviral activity and up-regulation of MHC class I molecules [66]. Because of possible therapy of melanoma, type I IFNs were extensively studied in keratinocytes and melanocytes [67]; of note, the IFNβ expression in vitro by undifferentiated, growth-arrested murine keratinocytes suggested that its production by terminally differentiated cells was associated with arrest of proliferation. Recently it was reported the induction of autophagy by type I and type II IFNs in cancer cells, a mechanism that may counteract the pro-apoptotic functions of IFNs [11,71,72], through the p38 MAPK pathway and ATF6 phosphorylation [72].

### 5.2. Cell differentiation

It can be modulated by IFNs, as shown by an endless list of reports. Type I and type II IFNs were shown to affect the erythropoiesis pathways [63,64,73]. Chronic IFNγ production may cause anemia and bone marrow failure, hence it may be involved in malignant hematopoietic malignancies [73]. Another IFN-regulated process is adypogenesis, that is inhibited by type I and II IFNs [74,75]. In normal thymocytes both IFNα and IFNγ regulate the expression of integrins (target for infiltrating lymphocytes) and the signaling induced by cell adhesion to fibronectin [76]. Moreover, IFNγ induces CXCR3-binding chemokines, which in turn recruit Th1 lymphocytes, with an important role in the initiation of autoimmune thyroiditis.

### 5.3. Immunomodulation

IFNs are potent immunomodulators, especially IFNγ; among the IFNα subtypes, each has its own immunomodulatory pattern [77]. In general, IFNs stimulate already differentiated cells in the short term, while, by growth inhibition, in the long term or with higher IFN concentrations, they may reduce the replacement of exhausted cells with their precursors. Immunomodulatory effects include enhancement of surface molecules such as MHC (major histocompatibility complex) antigens, several receptors, and modulation of the activation and differentiation of effector cells, as monocyte/macrophages, dendritic cells (DC), B, T and NK cells. Type I and III IFNs and, with higher efficiency, type II IFN upregulate the expression of class I MHC and co-stimulatory molecules by tissue cells and immune cells, as the DCs, that differentiate into efficient antigen- and self-antigen-presenting cells, leading to activation of quiescent reactive T helper cells [66,78–80]. The expression of class II MHC molecules is upregulated by all three IFN types, being the type II the most active [81,82]. The effect of the latter IFN can be interfered by type I IFNs [83]. The activation of DR and of chemokine receptors may modify the phenotype (and recognition of progeny virions), and virus binding on the membrane [84,85]. Type I IFNs thus function to elevate both innate and adaptive immune responses, with induction of cytokines and chemokines, activation and differentiation of CD4+ T cells and CTLs, the activation and differentiation of B cells, the production of antibodies and the switching of immunoglobulin (Ig) isotypes [61,66,77]. Type III IFNs were not demonstrated to increase antibody formation, and were shown to modulate Th1/Th2 cells balance through a different mechanism from type I IFNs [66]. IFNγ, but not IFNα or IFNβ can induce neutrophils to suppress lymphocyte proliferation through the expression of programmed death ligand 1 (PD-L1) [86]. Type II IFN is essential also in immunity intracellular non-viral parasites such as Toxoplasma gondii, Cryptosporidium parvum, Leishmania major, Trypanosoma cruzi, etc., and elicits strong cell-autonomous killing of intracellular parasites; also type I IFN, however is induced during these infections: it does not exert an intrinsic control of parasites, but its signaling recruits NK cells, which then mediate parasite killing by producing type II IFN [87].

### 5.4. Interferon-induced diseases

Dysregulation in production/signaling of all IFN types are associated to a variety of pathologies. Activation of IFNα pathways were related to several autoimmune diseases, such as systemic

---

**Table 3**

Spectrum of biological activities of the interferons. See text for details and references.

| Activity                                      | Type I IFN | Type II IFN | Type III IFN |
|-----------------------------------------------|-----------|-------------|--------------|
| Inducibility by virus infections              | ++++      | +++         | ++           |
| Induction of antiviral effectors              | +++       | ++          | ++           |
| Cell growth inhibition                        | ++        | +++         | +            |
| Induction of autophagy                        | ++        | ++          | ns           |
| Stimulation/inhibition of cell differentiation | ++        | +++         | ns           |
| Stimulation of MHC class I antigens           | ++        | +++         | +            |
| Stimulation of MHC class II antigens          | ++        | +++         | ns           |
| Stimulation/inhibition of phagocytosis        | ++        | +++         | ns           |
| Stimulation/inhibition of antibody production | ++        | +++         | ns           |
| Inhibition of intracellular parasites         | +, indirect | ++, direct | ns           |
| Induction of IFN, cytokines and chemokines    | +         | ++          | +            |
| Induction of neurologic symptoms              | ++        | ++          | –            |
| Specific receptor distribution in the body    | Ubiquitous | Ubiquitous | Tissue-restricted |

* Cellular genes with p-value <0.05 and fold change ≥2, according to http://www.interferome.org [60].
* ns: not studied, so far.
lupus erythematosus, Addison's disease, etc. [88]. Miscarriage of humans and animals has been associated with higher levels of IFN, that, on the other hand, is involved in maintaining the decidual layer and vascular remodeling in the uterus [89]. Abnormality in IFN-stimulated gene patterns, causing failures in immunotolerance in early childhood were proposed to be contribute to the development of type 1 diabetes and cases of type 1 diabetes were also related to treatments with pegylated IFN and ribavirin for chronic hepatitis C [90]. Cardiovascular complications can be observed in IFN-treated subjects (arrhythmia, myocarditis, reversible hypertension, ischemic heart disease, pericarditis and pericardial effusion, cardiomyopathy) and are generally reversible [88]. Sarcoidosis, a systemic chronic granulomatous disease of unknown cause, is a rare adverse effect from the use of type I IFNα and IFNβ, that reflects an exaggerated cell-mediated immune response to an unknown persistent antigen, with higher levels of circulating IFNγ [91]. Thyroid dysfunctions in IFN-treated patients were observed since 1985 [92], and are still a significant problem for patients receiving either IFNα or IFNβ; in vitro and animal studies showed that thyroid inflammation and autoimmune involvement direct effects (increased expression of thyroid differentiation) as well as activation of destructive bystander immune responses [93]. Significant exacerbations were caused by treatment of multiple sclerosis patients with IFN, while IFNβ is currently given as the current and seems to be more potent than IFNα [94,95]. In the EAE animal model of multiple sclerosis, a regulatory role of Type III IFN-producing CD4+ T cells conferring protection against EAE was proposed [96]. Depression and other cognitive and psychiatric disturbances are reported by approximately half of the patients treated with IFNα for chronic hepatitis C and B. Behget's syndrome, melanoma and lymphoma [97]. IFNα determines abnormalities of the hypothalamo-pituitary-adrenal axis and disturbances of brain metabolism, and interferes with neurotrophic signaling, thus hindered neurite outgrowth, synaptic plasticity, endogenous neurogenesis and neuronal survival [97]. Comparing patients receiving pegylated IFNα plus ribavirin with those receiving IFNβ plus ribavirin, it was found that depressive symptoms were more prevalent following IFNα than IFNβ treatment [98]. In mice, IFNα was reported either to promote antidepressant-like effect associated with an increase in brain serotonin turn over, or to promote a depression-like phenotype, mediated by suppression of hippocampal neurogenesis and induction of depression [99], while the lack of IFNγ increased anxiety-like and depression-like behaviors of IFNγ-knocked out animals, suggesting that IFNγ is involved in hippocampal neurogenesis and CNS plasticity [100].

6. Concluding remarks

Interferons have extraordinary antiviral efficacy; therefore viruses have developed multiple strategies of immune evasion to counteract IFN induction and signaling and the interferon-induced effector molecules. During the last decades, IFNs were shown to display a multifaceted, Janus-like congers of activities, with synergisms and antagonisms between IFN types. Because of the multitude of IFN-induced genes, also opposite effects can be determined by the same IFN, depending on timing and dosages, and IFNs may have both beneficial and detrimental effects, depending on the disease context. Genetic diversity, with polymorphisms and mutations, can modulate the extent of IFN responses and the susceptibility to infections, and genetic and epigenetic variations within the IFN genes and in those associated with sensing/signaling/response can be linked to diseases. On the whole, IFNs are pleiotropic biologic response modifiers, that, upon activation of thousands genes, induce a broad spectrum of activities, regulating cell cycle, differentiation, plasma membrane molecules, release of mediators, etc., that can be relevant for cell proliferation, innate and adaptive immunity, hematopoiesis, angiogenesis and other body functions.

Conflicts of interest

The authors declare that they have no competing interests.

Acknowledgements

This work was partly supported by grants from Italian Ministry of Health, Ricerca Corrente and Ricerca Finalizzata (M.R.C.), and from CARITRO 2013 (A.D.). E.U. was funded by a grant from Regione Autonoma Sardegna 2013 (Master & Back Program).

References

[1] Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258–67.
[2] Nagano Y, Kojima Y. Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus. C R Seances Soc Biol Fil 1958;152:1627–9.
[3] Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778–809.
[4] Touzet M, Soumelis V, Asselah T. A dive into the complexity of type I interferon antiviral functions. J Hepatol 2012;56:726–78.
[5] Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohaemagglutinin. Science 1965;149:310–1.
[6] Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69–76.
[7] Sheppard P, Kindsvogel W, Xu W, Henderson K Schlutsmeier S, Whitemore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63–8.
[8] Donnelly RP, Kotenko Interferon: a new addition to an old family. Interferon Cytokine Res 2010;30:555–64.
[9] Iavshik LB, Donin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36–49.
[10] Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8–32.
[11] Schneisser H, Bekisz J, Zoon KC. New function of type I IFN: induction of autophagy. J Interferon Cytokine Res 2014;34:71–8.
[12] Lopalucka K, Reluščiková I, Betákrová T, Skovranová L, Tomášková J, Lukáčková L, et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol 2013;57:171–9.
[13] Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432–6.
[14] Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but not a whole. Cytokine Growth Factor Rev 2002;13:223–40.
[15] Renaud JC. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003;3:667–76.
[16] Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004;22:929–79.
[17] Kotenko SV, Langer JA. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 2004;4:593–608.
[18] Zhang SY, Boisson-Dupuis S, Chapprig A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008;226:29–40.
[19] Jouanguy E, Zhang SY, Chappier A, Sancho-Shimizu V, Puel A, et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007;89:87–83.
[20] Newport MJ, Huxley CM, Huston S, Hawleywicz CM, Oosta BA, Williamson R, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941–9.
[21] Jouanguy E, Altare F, Lamahsedi S, Rey P, Emile JF, Newport M, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calm- ette-Guérin infection. N Engl J Med 1996;335:1956–61.
[22] Smith NL, Denning DW. Clinical implications of interferon gamma genetic and epigenetic variants. Immunology 2014. http://dx.doi.org/10.1111/imm.12362. Accepted Article.
[23] Decaturhamin AS. Mechanisms underlying the inhibition of interferon sig- naling by viruses. Virulence 2014;5:270–77.
[24] van Montfoort N, Olagnier D, Hiscott J. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev 2014. pii:S1359-6101(14)00089-6.
[25] Orzalli MH, Knipe DM. Cellular sensing of viral DNA and viral evasion mechanisms. Annu Rev Microbiol 2014;68:477–92.
[26] Haller D, Kochs C, Weber F. Interferon, MX, and viral countermeasures. Cytokine Growth Factor Rev 2007;18:425–33.
[27] Chiang JJ, Davis ME, Gack MJ. Regulation of RIG-I-like receptor signaling by host and viral proteins. Cytokine Growth Factor Rev 2014. pii:S1359-6101(14)00059-8.
Concurrent immune responses to varicella-zoster virus infection persist for years in immunocompetent individuals. These responses include neutralizing antibodies, T-cell responses, and interferons. Among these, interferons play a central role in antiviral defense. Interferon-alpha (IFN-α) and interferon-beta (IFN-β) are the most studied interferons in the context of varicella-zoster virus (VZV) infection. IFN-α and IFN-β are produced by many cell types upon infection with VZV, including keratinocytes, fibroblasts, and immune cells. These interferons induce a broad range of antiviral effects, including the inhibition of viral replication, the induction of various cytoskeletal and cell surface proteins, and the modulation of immune responses.

IFN-α and IFN-β bind to their cognate receptors on the cell surface, which are co-stimulated by Toll-like receptor (TLR) signaling. This leads to the activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways, resulting in the induction of various interferon-stimulated genes (ISGs) and the activation of innate immune responses. IFN-α and IFN-β also induce the expression of chemokines, cytokines, and other pro-inflammatory mediators, which further contribute to the antiviral response.

In addition to their direct antiviral effects, IFN-α and IFN-β also modulate the adaptive immune response to VZV. They are involved in the induction of Th1 and Th17 polarization, the expansion of CD8+ T-cells, and the differentiation of natural killer (NK) cells. IFN-α and IFN-β also promote the differentiation of dendritic cells (DCs) into mature DCs, which are capable of presenting VZV antigen to CD8+ T-cells and inducing Th1 and Th17 responses.

IFN-α and IFN-β also have important therapeutic implications in the treatment of VZV infections. They are used in the treatment of herpes zoster and may be effective in reducing the duration and severity of the infection. IFN-α and IFN-β also have anti-inflammatory effects, which may be beneficial in the treatment of VZV infections with systemic complications, such as encephalitis or meningitis.

In summary, IFN-α and IFN-β are crucial components of the immune response to VZV infection. They play a critical role in the induction of direct antiviral effects and the modulation of the adaptive immune response. Further studies are needed to fully understand the mechanisms of action of IFN-α and IFN-β in the context of VZV infection and to identify potential therapeutic targets for the development of new antiviral agents.
Dr. Maria R. Capobianchi is PhD in Microbiology and Virology. She has been involved in research activity on viruses since 1977, when she joined the Institute of Virology at the University of Rome Medical School as fellow, and in 1981 got permanent position. Since 2000, Dr. Capobianchi is the Director of the Laboratory of Virology at the National Institute for Infectious Diseases, Rome, where she is in charge of diagnostic and research activity on viral diseases. Main scientific interests: innate immunity and defence mechanisms against viruses; Interferon induction and action; Pathogenesis of persistent viral infections; Biosafety; Laboratory alert and preparedness to emerging viral diseases. As of October 2014, Dr. Capobianchi is listed as Author or co-author of more than 300 indexed scientific articles, with more than 5000 citations, H index 38.

Elena Uleri, Ph.D., is a Postdoctoral fellow at the Virology Section of the Department of Biomedical Sciences, University of Sassari (Italy). She earned her doctorate in Fundamental and Clinical Virology at University of Sassari in consortium with University of Pisa (Italy), where she studied the role of human endogenous retroviruses HERV-Ws in the pathogenesis of Multiple Sclerosis (MS). As a Visiting research scholar at Department of Neurovirology of Temple University, Philadelphia (USA), she studied the interplay between host restriction factors and JC virus life cycle in PML and animal tumors JCV-induced. She is currently focused on the role of JCV in colon cancer and on the modulation of host factors by MS drugs that could be involved in JCV reactivation, on the mechanism by which HIV tat reactivates HERV-Ws expression and on interactions between viruses and HERV-W relevant in neurodegenerative diseases, on the interferon and cytokines role in the modulation of HERV-Ws. She has a broad background in molecular biology. She is member of the Italian Society of Virology (SIV).

Claudia Caglioti graduated in Biology in 2012 at Roma Tre University (Italy). From October 2010 to January 2013 she attended the Laboratory of Virology at National Institute for Infectious Diseases “L. Spallanzani” in Rome, for developing her experimental thesis. Since 2013 she is attending the Postgraduate School in Microbiology and Virology. Currently she is a research fellow at the National Institute for Infectious Diseases “L. Spallanzani”, where she is developing her PhD thesis focused on “Molecular basis of severe influenza A virus respiratory syndromes (pandemic and seasonal): study of viral evolution and identification of prognostic genetic markers”.

Antonina ( Ninella) Dolei received her specialization/ doctoral degree in Microbiology from the University of Rome in 1975 and in Virology from the University of Bologna in 1977. She became assistant professor of Virology, Faculty of Medicine at La Sapienza University, Rome in 1981. After serving as associate professor of Pathology, Faculty of Sciences at the University of Camerino, Italy until 1985, she joined the Faculty of Medicine at the University of Sassari as full professor of Virology. Since 1975, she studies INTERFERONS (antiretroviral and cell-modulating aspects, protective and immunopathogenic activities) and RETROVIRUSES (HIV pathogenesis, since 1984, and human endogenous retroviruses (HERV) in the pathogenesis of multiple sclerosis and of neuroAIDS, since 1998; ONGOING STUDIES: activation of HERV-Ws in pathogenic mechanisms linked to neurodegeneration and cancer, and as prognostic biomarker of multiple sclerosis progression and therapy outcome; immunosubversion of host defenses by retroviruses. She was co-founder of the Italian Society for Virology (2001, now serving as vice-President), and co-founder of the European Society for Virology (2009); she is in the board of directors of the International Society of Neurovirology, and in the Nomenclature Committee of the International Cytokine and Interferon Society, being member of the Interferon society from the beginnings (SIR, ISCR and now ICS).